Articles tagged "Alloantibodies"

2022 American Transplant Congress
Desensitization Protocol to Prevent Severe Oliguric Antibody-Mediated Rejection
H. Ishida¹, K. Unagami¹, T. Kamzawa¹, K. Omoto¹, H. Shimizu¹, K. Tanabe²
¹Tokyo Womens, Tokyo 162-8666, Japan, ²Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Antibody-mediated rejection in a case with a positive crossmatch test can be severe and result in sudden onset of oliguria and sometimes, anuria, leading…
2022 American Transplant Congress
Regulatory T and B Cell Responses Are Equally Compromised During Antibody-Mediated Rejection of Kidney Allografts
K. Louis¹, P. Fadakar², C. Macedo², M. Yamada², M. Lucas², X. Gu², A. Zeevi², P. Randhawa², C. Lefaucheur³, D. Metes²
¹Inserm U976, Human Immunology and Immunopathology, Paris, France, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Inserm U970, Paris Translational Research Center for Organ Transplantation, Paris, France
*Purpose: Although considerable advances have been made in understanding the cellular effector mechanisms responsible for donor-specific antibody (DSA) generation leading to antibody-mediated rejection (ABMR), the…
2022 American Transplant Congress
The Impact of Soluble Human Leukocyte Antigen (HLA) on Renal Antibody-Mediated Rejection (AMR) After Simultaneous Liver Kidney Transplantation (SLKT)
H. Me¹, A. Jaramillo¹, D. Ramon¹, L. G. Olsen¹, R. Heilman¹, H. Khamash¹, T. Mohanakumar², R. Ravichandran²
¹Mayo Clinic, Phoenix, AZ, ²St. Joseph's Hospital and Medical Center, Phoenix, AZ
*Purpose: The lower incidence of AMR and higher incidence of rejection-free grafts survival in SLKT recipients as compared to kidney transplant recipients have been clearly…
2022 American Transplant Congress
Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial
N. Wilson¹, S. R. Reese², L. Ptak³, F. Aziz², S. Parajuli², V. Jucaud⁴, S. Denham⁴, A. Mishra⁵, P. Hematti⁵, A. Djamali²
¹University of Wisconsin, Madison, WI, ²Medicine, University of Wisconsin, Madison, WI, ³Administration, University of Wisconsin, Madison, WI, ⁴Terasaki Institute, Los Angeles, CA, ⁵UW Comprehensive Cancer Center, University of Wisconsin, Madison, WI
*Purpose: Ixazomib is a second-generation oral proteasome inhibitor, FDA approved for the treatment of refractory multiple myeloma. The purpose of the study was (1) to…
2022 American Transplant Congress
ABO Hemagglutination Titres Do Not Accurately Reflect ABO Antibody Levels
A. Halpin¹, T. Ellis², J. Pearcey², B. Motyka², T. L. Lowary³, C. Cairo⁴, S. Maier², L. J. West⁵
¹Pediatrics/Dept of Laboratory Medicine, University of Alberta/Alberta Precision Laboratories, Edmonton, AB, Canada, ²Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Academia Sinica, Institute of Biological Chemistry, Taipei, Taiwan, ⁴Chemistry, University of Alberta, Edmonton, AB, Canada, ⁵Pediatrics, University of Alberta, Canadian Donation and Transplant Research Program, Edmonton, AB, Canada
*Purpose: ABO antibody (ABO-Ab) quantification is essential for risk assessment for ABO-incompatible (ABOi) transplantation, but the hemagglutination assay (HA) for ABO-Ab titres is known to…
2022 American Transplant Congress
Comprehensive Profiling of Monocytes During Cellular (TCMR) or Mixed Antibody-Mediated Rejection (ABMR) After Kidney Transplantation
C. Macedo¹, E. Bailly¹, K. Louis², X. Gu¹, M. Lucas¹, A. Zeevi¹, P. Randhawa¹, A. Bansal³, D. Metes¹
¹Starzl Transplantation Institute, Pittsburgh, PA, ²INSERM UMR-S976, Paris, France, ³University of Pittsburgh, Pittsburgh, PA
*Purpose: Monocytes play an important role in the immune defense by initiating adaptive immunity. They are heterogeneous, plastic, and present different subsets: classical (CD14++CD16-), intermediate…
2022 American Transplant Congress
De Novo Donor-Specific Antibody Development in Heart Transplant Recipients Following COVID-19 Vaccination
M. Cheng¹, O. Behbahani-Nejad¹, D. Gupta²
¹Internal Medicine, Emory University School of Medicine, Atlanta, GA, ²Internal Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA
*Purpose: To determine the incidence of de novo donor-specific antibodies (DSAs) in recipients of orthotopic heart transplants (OHT) who received an mRNA vaccine against SARS-CoV-2.*Methods:…
2022 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh, F. Messner, Y. Guo, G. Brandacher
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2022 American Transplant Congress
Lung Allograft-Resident Eosinophils Maintain Long-Term Graft Integrity by Restraining Humoral Alloimmunity
Z. Mei¹, Y. Guo¹, D. Li¹, M. Khalil¹, A. Banerjee¹, A. Gelman², D. Kreisel², A. Krupnick³
¹Department of Surgery, University of Maryland, Baltimore, Baltimore, MD, ²Washington University in St. Louis, St. Louis, MO, ³Department of Surgery, University of Maryland, Baltimore, baltimore, MD
*Purpose: The finding that eosinophils facilitate immunosuppression-mediated acceptance of murine lung allograft by downregulating alloreactive CD8+ T cells has been recently described by our group.…
2022 American Transplant Congress
Association of Pre-Transplant Anti A1 IgM Antibody Titers with Survival Outcomes in A2/A2B to B Kidney Transplantation
M. Fallahzadeh, D. Shaffer, A. El Chediak, I. Feurer, S. Rega, J. L. Triozzi, S. Shawar
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The new kidney allocation system implemented in 2014 has allowed blood type B recipients to receive kidneys from A2/A2B donors. Although many centers use…